Periodic Reporting for period 1 - KvasirAccelerator (The first utility-oriented, agnostic software platform for quantum-centric drug discovery)

Pharma companies are striving to meet the ever-increasing complexity of drug R&D, while not wasting money upfront (~€2.5Bn average development costs, 42-50% of which is spent on drug discovery/preclinical development) and increasing trial success rates (currently